Synlogic (0A8U) AI Stock Analysis

0 Followers

Synlogic

(LSE:0A8U)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-Free Balance SheetDebt falling to zero materially reduces fixed financial obligations and refinancing exposure, while positive equity provides a cushion for continued development. This improves financial flexibility and lowers balance-sheet risk, although it does not by itself establish operating self-sufficiency.

Negative Factors

No Commercial RevenueThe absence of recurring commercial revenue leaves Synlogic dependent on partnerships, financing, or other external sources to fund development. It also limits earnings visibility and operating leverage, making future performance highly dependent on successful clinical progress.

Synlogic (0A8U) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $13.47M
Dividend Yield: ―
Average Volume (3M): 1,000
Price to Earnings (P/E): -6.3
Beta (1Y): 1.31
Revenue Growth: ―
EPS Growth: 35.21%
Country: UK
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Synlogic Business Overview & Revenue Model

Company Description

Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.

Synlogic Risk Analysis

Synlogic disclosed 34 risk factors in its most recent earnings report. Synlogic reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Synlogic Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0A8U against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALLR	44Neutral	$14.88M	-1.15	-152.77%	―	―	91.38%
ICU	44Neutral	$10.21M	-0.30	-261.10%	―	145.74%	75.46%
LSTA	42Neutral	$12.96M	-0.75	-113.79%	―	-90.65%	26.48%
APVO	41Neutral	$1.38M	-0.00	-201.49%	―	―	99.41%
CING	41Neutral	$67.47M	-0.89	-238.41%	―	―	37.29%

* Healthcare Sector Average

Performance Comparison

GB:0A8U and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0A8U	Synlogic Inc	1.10	-0.69	-38.55%
LSTA	Lisata Therapeutics, Inc.	1.28	-0.81	-38.76%
APVO	Aptevo	0.66	-24.00	-97.32%
ICU	Seastar Medical Holding Corporation	1.05	-1.98	-65.36%
CING	Cingulate, Inc.	4.49	1.16	34.83%
ALLR	Allarity Therapeutics, Inc.	0.91	-0.21	-18.48%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Synlogic AI Stock Analysis